Trading Update
Summary by AI BETAClose X
Halma plc
Trading update
24 September 2026
Halma, the global group of life-saving technology companies focused on growing a safer, cleaner, healthier future for everyone, every day, today releases its scheduled trading update ahead of its half year end on 30 September 2026.
Strong progress in the first half; full year Adjusted1 EBIT margin2 guidance increased
We have made strong progress in the first half of this financial year, delivering broad-based growth against a backdrop of continued economic, geopolitical and market uncertainty. Our performance reflects the strength of our Sustainable Growth Model, including decades of disciplined choices around the markets we operate in, the companies we acquire and the leaders we trust to run them. It also reflects the autonomy our model gives our talented teams to respond with agility to changes in their markets. Our approach enables us to invest with confidence and to actively manage our portfolio, delivering compounding growth and returns over the long term.
Based on our progress in the year to date and our current expectations for the remainder of the year, we continue to expect low double-digit percentage organic3 constant currency revenue growth for the year as a whole. This guidance includes premium4 growth of approximately five percentage points from our photonics business, implying an organic3 constant currency photonics growth rate of approximately 30%. Adjusted1 EBIT margin2 in the 2027 full year is now expected to be in the range of 23.5% to 24%. This compares to our previous guidance for margin to be in line with the 2026 financial year at around 22.7%5, with the increase reflecting continued good operational delivery and favourable product and portfolio mix across all three sectors, including the positive impact of recent acquisitions and disposals.
This guidance is supported by order intake which remains ahead of both revenue in the year to date and the comparable period last year.
The recent appreciation of Sterling against the US Dollar and Euro, if maintained, is expected to result in a negative currency translation effect on the Group's results6.
Record investment in acquisitions; healthy acquisition pipeline
Our cash generation and robust financial position support continued investment in future growth, both organically and through acquisitions. We have maintained strong M&A momentum, completing six acquisitions in the year to date, investing a record £515m (on a cash- and debt-free maximum total consideration basis7). We continue to have a healthy acquisition pipeline across all three sectors.
We also continue to actively manage our portfolio of global businesses to ensure capital is allocated towards those opportunities with the greatest potential to deliver sustainable growth and returns, while remaining aligned with our purpose of growing a safer, cleaner, healthier future for everyone, every day. Reflecting this disciplined approach, we have completed three disposals in the period, realising approximately £83m, net of disposal costs8.
Half Year Results
The Group’s results for the half year ending 30 September 2026 will be released on 19 November 2026.
For further information, please contact:
Halma plc
|
Marc Ronchetti, Group Chief Executive |
+44 (0)1494 721 111 |
|
Carole Cran, Chief Financial Officer |
+44 (0)1494 721 111 |
|
Melanie Horton, Co-Head of Investor Relations |
+44 (0) 7554 013 396 |
|
Charles King, Co-Head of Investor Relations |
+44 (0) 7776 685 948 |
MHP
|
Oliver Hughes / Rachel Farrington / Ollie Hoare |
+44 (0)7801 894 577 / +44 (0)7817 458 804 / halma@mhpgroup.com |
Notes:
1. Adjusted to remove the amortisation and impairment of acquired intangible assets; acquisition items; significant restructuring costs; profit or loss on disposal of operations, and impairment of associates.
2. Adjusted1 EBIT margin is defined as Adjusted1 Earnings before Interest and Taxation from continuing operations expressed as a percentage of revenue from continuing operations.
3. Organic measures exclude the effect of movements in foreign exchange rates on the translation of revenue and Adjusted1 Profit into Sterling, as well as acquisitions in the year following completion and disposals.
4. The photonics premium is determined as the incremental contribution to Group organic3 revenue growth from the photonics business in excess of the Group’s long-term organic3 revenue growth rate of 7%. It captures the portion of Group organic3 revenue growth, expressed in percentage points, that would not have occurred had photonics grown at the Group’s long-term organic3 revenue growth rate.
5. On 15 May 2025, Nuvonic, an Environmental & Analysis Sector company, granted FluidSmile Fluid Tech Ltd (FluidSmile), a longstanding partner in China, an exclusive trademark licence and related manufacturing and distribution rights to sell certain Nuvonic products in China and other agreed southeastern Asian markets, for RMB95m (£9.9m). Nuvonic also acquired a 35% associate interest in FluidSmile for RMB95m on the same date. As a result of these transactions, one-off revenue of £9.9m and Adjusted1 profit of £9.3m were recognised in financial year 2026, which constituted a 30bps increment to Adjusted1 EBIT margin2.
6. Sterling has strengthened in the year relative to the US Dollar and Euro and the currency translation impact on the Group's results for the financial year ended 31 March 2027 is expected to be negative. Based on current exchange rates of Sterling/US Dollar 1:1.35 and Sterling/Euro 1:1.17, we would expect approximately an £8m negative revenue effect and approximately a £2m negative profit effect in the 2027 financial year, compared to the 2026 financial year.
7. Of the six acquisitions made in the year to date, DCR Inspection Systems Ltd and Surgistar Inc were reported in the Group’s 2026 full year results announcement and disclosed in note 32 to our Annual Report and Accounts 2026. Since that time, we have made four further acquisitions (considerations given are all on a cash- and debt-free maximum total consideration basis):
- itemedical, a provider of digital platforms that integrates patient data in real time from different devices in hospitals, supporting clinical decision-making and workflow efficiency, acquired in June 2026 for €23m (approximately £20m), as a bolt on for SSG;
- Näslund Medical, a company specialising in fiducial marker technology used to support targeted cancer treatment, acquired in June 2026 for $45m (approximately £34m), as a bolt on for IZI Medical;
- Dreampath Diagnostics, a provider of automated systems that enable anatomical pathology laboratories to safely and efficiently track, store and manage patient tissue samples, acquired in July 2026 for €279m (approximately £238m); and
- Pyxis, a specialist provider of water quality monitoring and analysis technology, acquired in September 2026 for $200m (approximately £148m). Following the announcement on 2 September 2026, the acquisition of all three Pyxis companies has completed.
8. Of the three disposals made in the year to date, Labsphere and Cardios were reported in the Group’s 2026 full year results announcement and disclosed in note 32 to our Annual Report and Accounts 2026. In August 2026, we made one further disposal, of NovaBone, for $56m (approximately £42m), net of disposal costs. We currently expect no material gain or loss to be recognised on this disposal.
9. This Trading update is based upon unaudited management accounts information. Forward-looking statements have been made by the Directors in good faith using information available up until the date that they approved this statement. Forward-looking statements should be regarded with caution because of the inherent uncertainties in economic trends and business risks.
10. A copy of this announcement, together with other information about Halma, may be viewed on our website www.halma.com.
About Halma
Halma is a global group of life-saving technology companies, focused on growing a safer, cleaner, healthier future for everyone, every day.
Its purpose defines the three broad market areas where it operates:
|
Protecting people, assets and critical infrastructure by addressing safety risks in public, commercial and industrial environments, and supporting a safer, more sustainable future. |
|
Monitoring the environment and ensuring the quality and availability of life-critical resources, and enabling scientific research through advanced measurement, analysis and data transmission. |
|
Meeting the growing demand for healthcare as populations age and chronic conditions rise, by supporting the discovery of new cures, the prevention, diagnosis and treatment of patient conditions, and enabling the delivery of safer, more efficient healthcare. |
It employs over 9,000 people in more than 20 countries, with major operations in the UK, Europe, the US and Asia Pacific. Halma is listed on the London Stock Exchange (LON: HLMA) and is a constituent of the FTSE 100 index.
Halma has been named as one of Britain’s Most Admired Companies for the past seven years.
For more information www.halma.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 hour ago Frasers Group
- 1 hour ago Cavendish Financial
- 1 hour ago Diaceutics
- 1 hour ago AB Dynamics
- 15 hours ago Johnson Matthey